Description

(Glucagon-Like Peptide-1 Receptor Agonist – GLP-1R)

GLP-1S is a synthetic long-acting analog of human glucagon-like peptide-1 (GLP-1), developed to mimic the activity of endogenous incretin hormones that regulate glucose metabolism and energy balance. By selectively binding to and activating the GLP-1 receptor (GLP-1R), Semaglutide enhances insulin secretion, suppresses glucagon release, and delays gastric emptying in research models.

Its extended half-life—achieved through structural modification that enhances albumin binding—makes Semaglutide a widely studied compound for metabolic, obesity, and glucose-regulation research as part of the incretin-based therapeutic class.

---

Mechanism of Action (Based on Preclinical and Clinical Research):

• GLP-1 receptor activation: Stimulates glucose-dependent insulin secretion while inhibiting glucagon release.

• Gastric motility modulation: Slows gastric emptying to prolong nutrient absorption and satiety.

• Appetite suppression: Engages central GLP-1R pathways in the hypothalamus, influencing hunger regulation.

• Metabolic efficiency: Promotes improved lipid metabolism and insulin sensitivity in experimental systems.

• Extended duration: Albumin-binding modification extends biological activity up to one week in vivo.

---

Potential Benefits (Based on Preclinical Research):

• Enhanced glucose control and insulin responsiveness

• Reduced food intake and body-weight modulation

• Improved lipid and energy metabolism markers

• Cardiometabolic protection observed in experimental models

• Studied for applications in metabolic, obesity, and endocrine research

---

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.